Development
Novartis AG
NVS
$118.08
$1.241.06%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 8.01% | 12.30% | 7.84% | 3.37% | -20.05% |
| Total Other Revenue | -9.49% | 6.53% | 3.78% | -9.89% | 33.11% |
| Total Revenue | 7.39% | 12.14% | 7.71% | 3.07% | -18.90% |
| Cost of Revenue | 8.38% | 7.48% | 16.79% | -0.70% | -22.23% |
| Gross Profit | 7.05% | 13.83% | 5.39% | 4.70% | -17.72% |
| SG&A Expenses | 9.93% | 5.35% | -0.43% | -3.16% | -19.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 106.58% | -79.45% | -90.08% | -5.96% | -246.43% |
| Total Operating Expenses | 44.15% | -2.44% | -8.99% | -0.47% | -33.10% |
| Operating Income | -38.65% | 79.22% | 88.52% | 15.25% | 10.43% |
| Income Before Tax | 51.50% | -2.21% | 81.51% | 2.66% | -90.74% |
| Income Tax Expenses | -202.76% | -84.82% | 95.81% | -0.89% | -60.62% |
| Earnings from Continuing Operations | 100.61% | 13.76% | 79.49% | 3.38% | -91.94% |
| Earnings from Discontinued Operations | 3,768.87% | 2.04% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00% | 0.00% | -133.33% | -- |
| Net Income | 478.44% | 11.95% | 36.72% | 3.20% | -91.01% |
| EBIT | -38.65% | 79.22% | 88.52% | 15.25% | 10.43% |
| EBITDA | -33.02% | 50.46% | 55.33% | 14.16% | 4.97% |
| EPS Basic | 500.29% | 17.65% | 43.85% | 8.81% | -90.55% |
| Normalized Basic EPS | -34.99% | 101.44% | 107.60% | 25.77% | -74.15% |
| EPS Diluted | 494.59% | 17.73% | 44.26% | 9.09% | -90.46% |
| Normalized Diluted EPS | -34.93% | 101.37% | 107.79% | 25.85% | -74.18% |
| Average Basic Shares Outstanding | -6.01% | -4.85% | -5.16% | -5.17% | -2.50% |
| Average Diluted Shares Outstanding | -6.01% | -4.82% | -5.19% | -5.23% | -2.49% |
| Dividend Per Share | 13.24% | -- | -- | -- | 1.77% |
| Payout Ratio | -1.00% | -- | -0.18% | -0.06% | -- |